Respiratory syncytial virus (RSV) is a common virus that affects the nose, throat, and lungs. For most healthy adults and ...

As the number of RSV infections rises, two recent studies found that protecting babies against the disease prevented ...

With babies being especially vulnerable to RSV, or respiratory syncytial virus, Iowa native Shawn Johnson East is raising ...

In 2023, the FDA and CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the monoclonal ...

Infants who receive nirsevimab may have a lower risk for hospitalisation for RSV-related lower respiratory tract infection ...

The study included 31,900 infants, 49.1% of whom received nirsevimab. HealthDay News — Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower ...

Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory infections among infants, particularly ...

Nirsevimab, a long-acting monoclonal antibody that confers passive immunity for infants up to 6 months old, was approved in ...

Shawn Johnson East, Olympic gymnastics gold medalist, said her son was hospitalized with RSV at age 1, prompting her mission ...

(Reuters) -Infant hospitalizations due to respiratory syncytial virus (RSV) infections in the United States dropped as much as 43% last year compared to previous years, following the widespread ...

As several European countries are currently detecting respiratory syncytial virus (RSV) infections, ECDC issues rapid scientific advice for policymakers and public health authorities on ways to ...

Peak season ranges from late December to mid-February every year, the CDC website says. Last year in North Carolina, RSV ...